High sensitivity C-reactive protein in cardiovascular disease and type 2 diabetes: evidence for a clinical role?

Libby P. Inflammation in atherosclerosis. Nature 2002 ;420:868-74.

Danesh J. , Whincup P. , Walker M. et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.

Ridker PM , Hennekens CH , Buring JE , Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.

Pearson TA , Mensah GA , Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.

Verma S. , Szmitko PE , Ridker PM C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2005;2:29-36; quiz 58.

Liao JK Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005;96:24F-33F.

Ridker PM , Cannon CP , Morrow D. et al. C-reactive protein levels and outcomes after statin therapy . N Engl J Med 2005;352:20-8.

Danesh J. , Wheeler JG , Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.

Greenland P. , O'Malley PG When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch Intern Med 2005;165:2454-6.

Wilson PW , Nam BH , Pencina M. , D'Agostino RB, Sr. , Benjamin EJ , O'Donnell CJ C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005;165:2473-8.

Lowe GD Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 2005;3:1618-27.

Sattar N. , McConnachie A. , O'Reilly D. et al. Inverse association between birth weight and C-reactive protein concentrations in the MIDSPAN Family Study. Arterioscler Thromb Vasc Biol 2004;24:583-7.

Miller M. , Zhan M. , Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 2005;165:2063-8.

Verma S. , Wang CH , Li SH et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-19.

Taylor KE , Giddings JC , van den Berg CW C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 2005;25:1225-30.

Hirschfield GM , Gallimore JR , Kahan MC et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 2005;102:8309-14.

Baigent C. , Keech A. , Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.

Casas JP , Shah T. , Cooper J. et al. C-reactive Protein is a Marker but not a Cause of Myocardial Infarction in Caucasian Men: Evidence against causality using Mendelian Randomisation . Int J Epidemiol. In press.

Koenig W. , Sund M. , Frohlich M. , Lowel H. , Hutchinson WL , Pepys MB Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987. Am J Epidemiol 2003;158:357-64.

Campbell B. , Badrick T. , Flatman R. , Kanowski D. Limited clinical utility of high-sensitivity plasma C-reactive protein assays. Ann Clin Biochem 2002;39:85-8.

Freeman DJ , Norrie J. , Caslake MJ et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study . Diabetes 2002;51:1596-600.

Sattar N. , Gaw A. , Scherbakova O. et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-19.

Timpson NJ , Lawlor DA , Harbord RM et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 2005;366:1954-9.

Haffner SM , Greenberg AS , Weston WM , Chen H. , Williams K. , Freed MI Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.

Haffner S. , Temprosa M. , Crandall J. et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005;54:1566-72.

Cai D. , Yuan M. , Frantz DF et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med